Home › Research › Drug development
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran E, De Strooper B.. Nature reviews. Drug discovery, 2022-02-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal of amyloid plaque from brains of patients with AD, and the FDA has recently granted accelerated approval to one of these, aducanumab, using reduction of amyloid plaque as a surrogate end point. The rationale for approval and the extent of the clinical benefit from these antibodies are under intense debate.
What this study adds
Evidence grade: Low
This is a narrative review. This review discusses four anti-amyloid antibodies that remove amyloid plaque, including aducanumab, which received accelerated approval using plaque reduction as a surrogate endpoint. It notes that the rationale for approval and the extent of clinical benefit are under intense debate, so it does not establish a cure or clear clinical benefit.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Karran, E., & De Strooper, B. (2022). The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature reviews. Drug discovery. https://doi.org/10.1038/s41573-022-00391-w
Vancouver
Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature reviews. Drug discovery. 2022. doi:10.1038/s41573-022-00391-w. PMID: 35177833.
BibTeX
@article{karran2022-35177833,
author = {Karran, E. and De Strooper, B.},
title = {{The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics}},
journal = {Nature reviews. Drug discovery},
year = {2022},
doi = {10.1038/s41573-022-00391-w},
pmid = {35177833},
url = {https://doi.org/10.1038/s41573-022-00391-w}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- However, four anti-Aβ antibodies have been shown to mediate the removal of amyloid plaque from brains of patients with AD, and the FDA has recently granted accelerated approval to one of these, aducanumab, using reduction of amyloid plaque as a surrogate end point.
- The rationale for approval and the extent of the clinical benefit from these antibodies are under intense debate.
- With the aim of informing this debate, we review clinical trial data for drugs that target Aβ from the perspective of the temporal interplay between the two pathognomonic protein aggregates in AD - Aβ plaques and tau neurofibrillary tangles - and their relationship to cognitive impairment, highlighting differences in drug properties that could affect their clinical performance.
- On this basis, we propose that Aβ pathology drives tau pathology, that amyloid plaque would need to be reduced to a low level (~20 centiloids) to reveal significant clinical benefit and that there will be a lag between the removal of amyloid and the potential to observe a clinical benefit.
Why it matters
This review discusses four anti-amyloid antibodies that remove amyloid plaque, including aducanumab, which received accelerated approval using plaque reduction as a surrogate endpoint. It notes that the rationale for approval and the extent of clinical benefit are under intense debate, so it does not establish a cure or clear clinical benefit.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 57/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nature reviews. Drug discovery) |
| Journal's citation record | 3 / 4 | Nature Reviews Drug Discovery: journal h-index 479 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 739 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 123.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 5 / 6 | Cited 26.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 18 other studies in this library |
| Still being cited | 4 / 4 | Cited 497 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Bart De Strooper: h-index 146 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35177833) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41573-022-00391-w
- PubMed: 35177833
- Original source →
- Free full text: Lirias (KU Leuven) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 43.
Later studies that cite this one
18 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Drug development from nearby years
Also in Drug development
104 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.